Quick Facts

• Primary Use: Management of the symptoms associated with intermittent claudication.
• Core Benefit: May help to increase the distance an individual can walk without experiencing discomfort.
• Therapeutic Focus: Addressing leg pain and cramping related to insufficient blood flow.

Plidol 100 (cilostazol) is an approved medication intended for the symptomatic relief of intermittent claudication. This condition is characterized by leg pain, cramping, or numbness that occurs during physical exertion, such as walking, due to reduced blood flow in the legs. The core therapeutic goal is to manage this discomfort.

Treatment with Plidol 100 may support an increase in the pain-free walking distance for affected individuals. It is considered a management option for patients whose symptoms have not sufficiently improved with lifestyle modifications alone, such as smoking cessation and increased exercise.

This medication is part of a comprehensive management strategy to improve peripheral circulation and overall well-being. Patients may begin to experience a positive change in symptoms within two to four weeks; however, the maximal benefit may take up to twelve weeks of consistent use. Plidol 100 may reduce the frequency of discomfort related to this vascular issue. Individuals should always discuss this treatment with a qualified healthcare professional.

Regulatory References

1. NIH DailyMed guidance for cilostazol

Official Eligibility and Exclusion Criteria

Official regulatory documents define specific populations who must not use this medicine. The main exclusion criteria, or contraindications, are based on pre-existing medical conditions and hypersensitivity.

Classification	Who Must Not Use (Contraindicated)
Heart/Cardiovascular	Patients with heart failure of any severity.
Hypersensitivity	Individuals with known or suspected hypersensitivity to the active ingredient (cilostazol) or any other component.

---

Classification	Use is Not Recommended or Restricted
Bleeding Risk	Patients with a hemostatic disorder or active pathological bleeding (e.g., intracranial hemorrhage) should avoid use.
Organ Function	Generally not recommended for patients with severe renal impairment (creatinine clearance leq 25 mL/min) or moderate or severe hepatic impairment due to a lack of safety data in these groups.
Age	Safety and effectiveness have not been established in the pediatric population.
Physiological State	Pregnancy status: May cause fetal harm. Lactation: It is not known if the drug passes into breast milk, and a decision must be made to either discontinue nursing or the medication.

The regulatory profile clearly establishes mandatory exclusions for individuals with heart failure and known allergies, while also advising against use in patients with significant organ impairment or existing bleeding disorders.

Plidol 100 (Cilostazol) has officially documented interaction patterns that regulate its use based on its metabolic pathway and pharmacological activity. The medicine is formally contraindicated in certain clinical contexts, including patients diagnosed with heart failure of any severity. Official regulatory documents also prohibit co-administration in patients concurrently receiving two or more additional agents that inhibit platelet aggregation or coagulation, such as aspirin or warfarin, due to a formally stated increased risk of hemorrhage.

Pharmacokinetic interactions impose significant constraints. Strong or moderate inhibitors of the CYP3A4 and CYP2C19 enzymes, including specific medicines like omeprazole or erythromycin, are documented to increase the systemic exposure (AUC and Cmax) of Plidol 100 and its active metabolites. This exposure alteration necessitates regulatory-defined procedural requirements. Furthermore, pharmacodynamic interactions may occur with single antiplatelet agents, where an additive effect on platelet function is noted, leading to a potential for increased bleeding.

Administration requires a specific timing separation from food. Taking the medicine with a high-fat meal or consuming substances like Grapefruit Juice is officially documented to increase the drug's maximum plasma concentration. For this reason, the labeling states the medicine must be taken on an empty stomach. Population-specific information notes that severe renal impairment alters protein binding and increases metabolite levels, and smoking is documented to decrease Plidol 100 exposure by approximately 20%.

How Plidol 100 Works

Plidol 100 exerts its pharmacodynamic action as a selective inhibitor of the enzyme phosphodiesterase type 3 (PDE3). This enzyme is present in various cell types, including vascular smooth muscle cells and circulating platelets. By blocking PDE3, the drug prevents the hydrolysis (breakdown) of the essential intracellular second messenger molecule, cyclic AMP (cAMP), leading to a targeted rise in its concentration within these cells.

Elevated cAMP levels initiate a cascade that results in the relaxation of arterial smooth muscle, which physically causes vasodilation and reduces peripheral vascular resistance. Simultaneously, the increased cAMP concentration in platelets inhibits the intracellular signaling processes required for their activation and aggregation. These dual mechanistic actions—vasodilation and platelet stabilization—collectively result in the physiological change of increased blood movement throughout the peripheral circulation.

How to Use Plidol 100 (Cilostazol): Administration Guidelines

Plidol 100 (Cilostazol) is prescribed for oral administration and is supplied in 50 mg and 100 mg tablet strengths. The medicine is designed to be taken according to a structured regimen that ensures consistent exposure.

---

Core Administration Protocol

The standard adult dose is 100 mg taken twice daily (b.i.d.). However, the dose is subject to modification based on a patient's concurrent drug regimen. The dosage is reduced to 50 mg twice daily when Plidol 100 is co-administered with certain strong inhibitors of the CYP3A4 or CYP2C19 enzyme systems. The drug must be taken on an empty stomach, generally defined as 30 minutes before or 2 hours after both breakfast and the evening meal. No specialized preparation (such as crushing or diluting) is required for the standard oral tablet form.

---

Duration and Special Conditions

Treatment is intended to continue for a defined period before its effect is formally evaluated. The full benefit of the medicine may require up to 12 weeks of consistent use. If no improvement in symptoms is observed after 3 months of therapy, discontinuation of the medication is typically considered.

Population Group	Official Dosing Guidance
Older Adults	No routine dosage adjustment required.
Renal Impairment	No adjustment necessary if creatinine clearance is greater than 25 ml/min.
Pediatric Patients	Safety and efficacy have not been established.

If a dose is missed, it should be skipped, and the patient should resume the standard twice-daily schedule with the next scheduled dose, without doubling the amount.

Research Evidence / Overview of Studies

This section provides an evidence-neutral overview of the clinical studies and published research that have examined Plidol 100. The information is strictly descriptive of the research design and findings, and does not constitute medical advice or a recommendation for use.

---

I. Pharmacological Research

Research has studied Plidol 100's activity in modulating nerve signal transmission via specific neural receptors. Research explored the drug's anti-inflammatory properties. The drug’s relatively short half-life was a factor in the trial designs.

---

II. Key Clinical Trial Findings

A. Neuropathic Pain

Research has investigated the effects of the drug in individuals with chronic neuropathic pain. Multiple placebo-controlled, randomized clinical trials (RCTs) have been conducted. Studies examined whether the drug was associated with changes in the duration or intensity of pain symptoms.

• Trial 1 (N=450): This study evaluated the drug versus a control group over 12 weeks. Findings indicated that participants receiving the drug reported lower average pain scores compared to the control group, as measured by a validated pain scale.
• Trial 2 (N=300): This trial examined a higher dose of the drug in patients with severe, treatment-resistant neuropathic pain. Results were mixed, with some participants showing a notable response, while others did not report significant benefit compared to baseline.

B. Combination Therapy for Pain Management

Research has evaluated the use of the drug in combination with other agents for severe pain management. This approach has been explored in cases where monotherapy did not achieve adequate symptom control.

• RCT Meta-analysis: A review of several trials evaluated the drug's use alongside a standard opioid analgesic. The analysis found that the addition of the study drug was correlated with a statistically significant reduction in the required daily dose of the opioid in the studied populations.

---

III. Adverse Event Reporting

Clinical trials have documented the reporting of adverse events in the studied populations, including findings for individuals with pre-existing conditions such as kidney failure.

• Observed A&E: Observed adverse events across all studied populations included somnolence (drowsiness), vertigo, and gastrointestinal discomfort. Reports noted that these events were often observed early in the trial protocols.
• Dosing Studies: The research reviewed in this section describes the dose ranges and titration schedules employed in the various trial protocols.

Common questions about Plidol 100 (FAQ)

---

Q: What is Plidol 100 used for besides the main condition?

A: The primary approved use for this medication is to help reduce the symptoms of intermittent claudication. This condition is characterized by leg pain that occurs with walking due to poor circulation. Official summaries also note that the drug has been investigated for potential use in the secondary prevention of stroke or transient ischemic attack (TIA).

Q: How quickly does Plidol 100 typically start to work?

A: Effects on blood cells are observed within a few hours of the first dose. However, a person may not feel any clinical improvement, such as easier walking, for 2 to 4 weeks. Regulatory studies indicate that the full therapeutic benefit may take up to 12 weeks of consistent use to be observed.

Q: How long does the effect of one Plidol 100 dose usually last?

A: The effects on blood cells generally last up to 12 hours following a single dose. The drug, along with its major active forms (metabolites), has an apparent elimination half-life of 11 to 13 hours. This duration of effect is consistent with the established administration schedule.

Q: Is Plidol 100 the same type of drug as [Similar Drug Name]? (Non-comparative)

A: Plidol 100 is officially classified as a selective Phosphodiesterase Type 3 (PDE III) Inhibitor. This means it works by targeting a specific enzyme in the body. This action causes vasodilation (widening of blood vessels) and inhibits platelet aggregation (clotting), which are actions described in official documents as supporting circulation.

Q: What are the most common reasons doctors prescribe Plidol 100?

A: According to official documentation, the most common approved reason for prescribing Plidol 100 is for the alleviation of symptoms related to intermittent claudication. This condition involves pain and cramping in the legs caused by reduced blood flow during exercise.

Q: Can Plidol 100 be taken indefinitely, or is it only for short-term use?

A: Treatment is typically evaluated by a healthcare professional after 3 months of consistent use. Regulatory guidelines state that if there is no clinically relevant improvement in walking ability after this period, discontinuation is typically considered.

Q: Are there any long-term effects of taking Plidol 100 that are generally known?

A: Clinical studies, including a long-term safety study (CASTLE), have examined the drug’s long-term profile. These studies were designed to monitor cardiovascular safety and found no increased risk of all-cause or cardiovascular mortality during the on-treatment period.

Q: Why is Plidol 100 only available as a 100mg dose?

A: The medication is available in both 50 mg and 100 mg tablet strengths. The 100 mg strength is the standard unit of the primary recommended dosage because clinical studies have shown it to be superior to the 50 mg dose for improving walking distance in patients.

Q: Does Plidol 100 interact with common over-the-counter pain relievers?

A: Short-term use alongside low-dose aspirin has been studied and shown to increase the drug's antiplatelet effects. Official guidance notes that individuals should inform their healthcare provider about all over-the-counter medications and pain relievers being used due to the potential for interactions.

Q: Is Plidol 100 safe for people with mild kidney problems?

A: Studies comparing subjects with mild to moderate renal (kidney) impairment to normal subjects found the overall pharmacological activity to be similar. Official information indicates that the drug is restricted or not recommended for patients who have severe renal impairment.

Q: What happens if I stop taking Plidol 100 suddenly?

A: When the drug is stopped, the antiplatelet effects on blood cells begin to subside after 48 hours. The effects return completely to baseline (before medication use) after 96 hours. Regulatory information indicates this process occurs without noted rebound or documentation of withdrawal symptoms.

Q: Is a headache a normal side effect when first starting Plidol 100?

A: Headache is consistently listed in clinical trial reports as one of the most commonly reported adverse events. Official reports indicate that these common events are frequently observed in patients when they first begin the course of treatment.

Q: Does Plidol 100 interact with alcohol?

A: Regulatory safety information indicates that alcohol consumption can increase the risk of side effects, such as dizziness. Alcohol may also increase the risk of stomach bleeding. Use of alcoholic beverages should be limited and discussed with a healthcare provider.

Q: Is Plidol 100 commonly prescribed for pain relief?

A: The approved use is specifically for the alleviation of symptoms of intermittent claudication. This condition involves pain in the legs caused by reduced blood flow when walking, meaning the prescription addresses the pain indirectly by improving circulation.

Q: Can people with high blood pressure use Plidol 100?

A: High blood pressure (hypertension) is not listed as an official contraindication. However, the drug is formally contraindicated for patients with heart failure of any severity or those with recent severe heart events.

Q: Is it OK to take vitamins or supplements while on Plidol 100?

A: Regulatory guidelines state that all vitamins, supplements, and non-prescription drugs should be noted to a healthcare provider. This is necessary because some of these products may interact with Plidol 100.

Q: Have researchers looked into new uses for Plidol 100?

A: Yes, regulatory summaries note that the drug has been investigated for potential uses beyond its primary indication. This includes being studied off-label for the secondary prevention of non-cardioembolic stroke or transient ischemic attack (TIA).

Q: Why is it important to follow the specified instructions for using Plidol 100?

A: Following instructions is critical because the drug’s absorption is significantly affected by food, especially a high-fat meal. Furthermore, dose adjustments are noted to be required when co-administered with certain other medicines to manage the risk of increased drug exposure.

Q: Does Plidol 100 affect my ability to drive or operate machinery?

A: Yes, official warnings state that Plidol 100 may affect alertness or coordination due to reported side effects like dizziness. Individuals should not drive or operate machinery until they are aware of how the medication affects them.

Q: Are there any common interactions between Plidol 100 and herbal remedies?

A: Regulatory documents state that all herbs and dietary supplements should be noted to a healthcare provider. This is due to the potential for some herbal remedies to interact with Plidol 100, which could alter the drug’s effects or increase the risk of bleeding.

Q: What are some alternatives to Plidol 100 that people often discuss?

A: Regulatory guidelines primarily compare Plidol 100 (Cilostazol) to the medication pentoxifylline. Clinical guidelines indicate that Plidol 100 is considered significantly more effective for improving walking distance and is often the first option discussed in official clinical guidelines.

Q: Can I take Plidol 100 if I am already taking medication for sleep?

A: Since the drug may cause drowsiness and is processed by certain liver enzymes (CYP3A4/2C19), regulatory guidance indicates that all sleep medications should be discussed with a healthcare provider. Some sleep aids may interact with Plidol 100 or require a dose adjustment.

Q: Do studies suggest Plidol 100 works better for certain groups of people?

A: Regulatory summaries of research indicate that the drug's cardiovascular benefits were maintained across various patient subgroups. These subgroups included people of different ages, sexes, and those with varying systolic blood pressure levels.

Q: How does the body generally eliminate Plidol 100 after it's taken?

A: The drug is eliminated predominantly by being extensively metabolized (broken down) in the liver by specific enzymes. The resulting breakdown products (metabolites) are then mostly excreted from the body via the urine.

Q: What does official research say about the effectiveness of Plidol 100?

A: Official clinical research consistently indicates that the drug significantly increases walking distance for patients with intermittent claudication. Studies have shown an improvement in the maximum walking distance of 40–60% compared to a placebo over 12 to 24 weeks.

Official Storage and Disposal Requirements

The storage and disposal requirements for Plidol 100 are strictly defined by regulatory guidelines to protect the integrity of the Acetylsalicylic Acid (ASA) and ensure environmental safety.

Requirement Type	Official Instruction
Temperature & Protection	Store at a Controlled Room Temperature (typically 15 C to 30 C) and protect from moisture. Avoid excessive heat and freezing.
Container & Handling	Keep the container tightly closed and store the medicine in the original package.
Child Safety	Keep out of the sight and reach of children (a mandatory requirement for all medicines).
Disposal Rule	Dispose of any unused or expired product in accordance with local regulations. It must not be released into the environment or sewage system.

Following these instructions is essential to prevent the active ingredient from degrading due to moisture exposure and to ensure proper final discarding of the medicinal product.